Medigene Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Medigene şirketinin toplam hissedar öz sermayesi €19.7M ve toplam borcu €0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla €28.8M ve €9.2M dir.

Anahtar bilgiler

Borç/özkaynak oranı

€0

Borç

Faiz karşılama oranı	n/a
Nakit	€14.02m
Eşitlik	€19.66m
Toplam yükümlülükler	€9.15m
Toplam varlıklar	€28.81m

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: MDG2 'nin kısa vadeli varlıkları ( €15.6M ) kısa vadeli yükümlülüklerini ( €6.5M ) aşıyor.

Uzun Vadeli Yükümlülükler: MDG2 şirketinin kısa vadeli varlıkları ( €15.6M ) uzun vadeli yükümlülüklerini ( €2.6M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: MDG2 borçsuzdur.

Borcun Azaltılması: MDG2 un 5 yıl önce borcu yoktu.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: MDG2 şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: Serbest nakit akışı her yıl % 10.2 oranında tarihsel oranda büyümeye devam ederse MDG2 un bir yıldan az nakit akışı süresi vardır.

Medigene Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Medigene AG Presents Progress on KRAS Library and UniTope & TraCR Technology at ESMO 2024

Second quarter 2024 earnings released: €0.15 loss per share (vs €0.17 loss in 2Q 2023)

Medigene AG Reaffirms Revenue Guidance for the Year 2024

Medigene AG Expands Patent Portfolio with the Patent Grant for its NY-ESO-1/LAGE 1a Targeted T Cell Receptor in China

New major risk - Financial position

Medigene AG to Report First Half, 2024 Results on Aug 14, 2024

Medigene Presents Efficient 6-Day TCR-T Therapy Production Process with High Stemness

New minor risk - Shareholder dilution

Medigene AG, Annual General Meeting, Jun 24, 2024

Medigene AG Presents Preclinical Data on Optimal Affinity TCRs Targeting the Neoantigen Mutant KRAS

Medigene Ag Maintains Earnings Guidance for 2024

Medigene Presents Superior TCR-T Cell Functionality by Inclusion of A Costimulatory Switch Protein

Medigene AG Presents Streamlined 6-Day, High Stemness Tcr-T Therapy Production Process

Medigene AG Presents Favorable Safety Profile of TCR-T Cells with Costimulatory Switch Protein at AACR Annual Meeting 2024

Medigene AG Secures European Patent for Its iM-TCR Technology

Full year 2023 earnings released: €0.66 loss per share (vs €0.34 loss in FY 2022)

Medigene Ag Provides Earnings Guidance for 2024

Medigene AG to Report Fiscal Year 2023 Results on Mar 28, 2024

New minor risk - Financial data availability

Medigene AG Announces Indication Selection for the Clinical Development of Its Lead 3Rd Generation Tcr-T Therapy Program in Solid Tumors

Medigene AG Maintains Financial Guidance for the Fiscal Year 2023

New major risk - Share price stability

Medigene AG Presents First Pre-Clinical Data of Optimal Affinity TCR Targeting mKRAS G12V Combined with a PD1-41BB Costimulatory Switch Protein Showing

Medigene to Present New Pre-Clinical Data for Pipeline TCR-T Therapies At the ESMO Congress 2023

Medigene AG Provides Revenue Guidance for 2023

New major risk - Financial position

New major risk - Financial position

Second quarter 2023 earnings released: €0.17 loss per share (vs €0.097 loss in 2Q 2022)

New major risk - Share price stability

Full year 2022 earnings released: €0.34 loss per share (vs €0.41 loss in FY 2021)

Medigene AG to Report Q3, 2023 Results on Oct 26, 2023

Medigene AG Maintains Revenue Guidance for the Fiscal Year 2022

Medigene AG Announces Appointment of Selwyn Ho as Member of the Executive Management Board with Effect of 25 July 2022

Medigene AG Announces Publication Details Augmentation of PRAME-Specific TCR-4 by PD1-41BB Switch Receptor

Medigene AG to Report Q3, 2022 Results on Nov 02, 2022

No longer forecast to breakeven

Medigene AG Reports Preliminary Efficacy and Immune Monitoring Data of Phase I of Phase I/II MDG1011 Trial in Blood Cancers

Medigene AG Achieves Positive Preliminary Results in Phase I of Phase I/II Trial of TCR-T Therapy MDG1011 in Blood Cancers

Forecast to breakeven in 2022

Medigene's PD1-41BB Switch Receptor Improves TCR-T Cell Functionality Against Solid Tumors

Forecast to breakeven in 2022

Medigene Confirms Revenue Guidance for 2021

Medigene AG Provides Earnings Guidance for the Year 2021

Advisor has left the company

Full year 2020 earnings released: €1.18 loss per share (vs €0.81 loss in FY 2019)

Medigene AG Announces Executive Changes

Medigene AG to Report Fiscal Year 2020 Final Results on Mar 25, 2021

Medigene AG Presents Further Encouraging Results from the Follow-Up of Acute Myeloid Leukemia Patients

Medigene AG Announces Discontinuation of MDG1021 Development Program

New 90-day high: €4.30

Medigene AG Announces Board Changes

Medigene AG, Annual General Meeting, Jun 24, 2021

Medigene AG Provides Update on MDG1011 Phase I/II clinical trial

New 90-day low - €4.84

Earnings released

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin